Pfizer Reaches a Fresh 52-Week High at $29.21
As seen on the 24/7 Wall St. homepage on October 14, 2026.
Pfizer hit a fresh 52-week high at $29.21, topping its September 2 peak. The drugmaker is now trading at levels no buyer from the past year is underwater on.
Continue ReadingShow less
Pfizer touched $29.21 on October 14, clearing the prior 52-week high set on September 2. That resets the technical ceiling: every share bought over the past year is now in the money, removing a layer of overhead selling pressure.
Pfizer spent the bulk of the year in the low-to-mid $20s before a sustained move carried it through the $27 range to the October 14 close. The break above the September 2 peak is the first time in a year that no prior buyers sit at a loss above the current price.
When a stock clears its 52-week high with no underwater holders left to sell into strength, the path of least resistance historically shifts. Whether Pfizer can sustain this level is the question every holder will be watching in the sessions ahead.
The September 2 peak had acted as a reference point for roughly six weeks before today's session cleared it. Even a slim margin is enough to register a fresh annual high on screening tools used by retail and institutional investors, which can draw incremental buying attention.
Sources
Mentioned: PFE